Alvaro Gomez Gonzalez

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(5):851-861
Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional study
Gomez A; Parodis I; Sjowall C
Article: LUPUS. 2024;33(6):615-628
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
Emamikia S; Gomez A; Adahl T; von Perner G; Enman Y; Chatzidionysiou K; Arkema EV; Parodis I
Article: RHEUMATOLOGY. 2024;63(2):338-348
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials
Gomez A; Jagerback S; Sjowall C; Parodis I
Article: RHEUMATOLOGY. 2024;:keae023
Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
Jagerback S; Gomez A; Parodis I
Article: RHEUMATOLOGY. 2023;62(12):3916-3923
Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
Hua N; Gomez A; Lindblom J; Emamikia S; Enman Y; Grannas D; Heintz E; Regardt M; Parodis I
Article: FRONTIERS IN MEDICINE. 2023;10:1247354
Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
Borg A; Lindblom J; Gomez A; Soltani A; Enman Y; Heintz E; Regardt M; Grannas D; Emamikia S; Parodis I
Article: RHEUMATOLOGY. 2022;61(12):4752-4762
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(22):13941
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
Parodis I; Gomez A; Lindblom J; Chow JW; Sjowall C; Sciascia S; Gatto M
Article: AUTOIMMUNITY REVIEWS. 2022;21(11):103188
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Gomez A; Parodis I
Article: FRONTIERS IN MEDICINE. 2022;9:852162
Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
Parodis I; Gomez A; Lindblom J; Chow JW; Doria A; Gatto M
Article: FRONTIERS IN MEDICINE. 2022;9:1092325
EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
Lindblom J; Zetterberg S; Emamikia S; Borg A; von Perner G; Enman Y; Heintz E; Regardt M; Grannas D; Gomez A; Parodis I
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:796508
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
Parodis I; Gomez A; Chow JW; Borg A; Lindblom J; Gatto M
Article: RHEUMATOLOGY. 2021;60(10):4703-4716
EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
Lindblom J; Gomez A; Borg A; Emamikia S; Ladakis D; Matilla J; Pehr M; Cobar F; Enman Y; Heintz E; Regardt M; Parodis I
Article: RHEUMATOLOGY. 2021;60(9):4205-4217
Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
Borg A; Gomez A; Cederlund A; Cobar F; Qiu V; Lindblom J; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: RHEUMATOLOGY. 2021;60(3):1260-1272
Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
Gomez A; Butrus FH; Johansson P; Akerstrom E; Soukka S; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: FRONTIERS IN MEDICINE. 2021;8:651249
Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
Gomez A; Qiu V; Cederlund A; Borg A; Lindblom J; Emamikia S; Enman Y; Lampa J; Parodis I
Article: RHEUMATOLOGY. 2020;59(11):3424-3434
Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis
Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau FA; Tamirou F
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(6):E1813-1813
Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
Gomez A; Soukka S; Johansson P; Akerstrom E; Emamikia S; Enman Y; Chatzidionysiou K; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020;21(10):E3463-3463
Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Parodis I; Akerstrom E; Sjowall C; Sohrabian A; Jonsen A; Gomez A; Frodlund M; Zickert A; Bengtsson AA; Roennelid J; Gunnarsson I
Article: RHEUMATOLOGY. 2019;58(12):2170-2176
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Article: LANCET RHEUMATOLOGY. 2019;1(3):E163-E173
Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2018;18(8):911-920
Smoking reduces the efficacy of belimumab in mucocutaneous lupus
Parodis I; Gomez A; Frodlund M; Jonsen A; Zickert A; Sjowall C; Bengtsson AA; Gunnarsson I
Journal article: PLOS ONE. 2017;12(9):e0184189
Aged blood factors decrease cellular responses associated with delayed gingival wound repair
Paz Saldias M; Fernandez C; Morgan A; Diaz C; Morales D; Jana F; Gomez A; Silva A; Briceno F; Oyarzun A; Maldonado F; Cerda O; Smith PC; Caceres M
Visa fler

Alla övriga publikationer

Review: RHEUMATOLOGY INTERNATIONAL. 2024;44(5):765-778
Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature
Tsoi A; Gomez A; Bostroem C; Pezzella D; Chow JW; Girard-Guyonvarc'h C; Stamm T; Arnaud L; Parodis I
Review: RHEUMATOLOGY ADVANCES IN PRACTICE. 2024;8(2):rkae037
Lifestyle interventions in the management of systemic sclerosis: a systematic review of the literature
Parodis I; Tsoi A; Gomez A; Chow JW; Girard-Guyonvarc'h C; Stamm T; Bostrom C
Review: RMD OPEN. 2023;9(3):e003297
Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
Parodis I; Gomez A; Tsoi A; Chow JW; Pezzella D; Girard C; Stamm TA; Bostrom C
Review: PATIENT RELATED OUTCOME MEASURES. 2023;14:1-13
Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
Gomez A; Enman Y; Parodis I
Letter: AUTOIMMUNITY REVIEWS. 2019;18(10):102372
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus
Hernandez-Breijo B; Gomez A; Soukka S; Johansson P; Parodis I
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1006-1007
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus
Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:777-778
ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC ACID INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Hernandez-Breijo B; Gomez A; Soukka S; Johansson P; Parodis I
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:761
PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:781-782
ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI